Mount Sinai Researchers Discover That Topical Treatment Improves Chronic Plaque Psoriasis
In phase 2b trials, roflumilast, a once-daily cream, demonstrated significant improvements in psoriasis signs and symptoms
Researchers at the Icahn School of Medicine report that roflumilast cream (ARQ-151), which contains a highly potent, selective phosphodiesterase-4 (PDE4) inhibitor demonstrated significant improvements in patients with psoriasis signs and symptoms in as early as two weeks. The phase 2b trial results showed that when patients with plaque psoriasis applied topical roflumilast once-daily they reported clear skin as well as improvement in itch and burden of disease. The results of the paper were published online in The New England Journal of Medicine.
According to Mark Lebwohl, MD, Waldman Professor and Chair of Dermatology at the Icahn School of Medicine at Mount Sinai, and lead investigator of the study, the results are particularly encouraging for patients who need new and better options to treat this chronic skin disease. “Plaque psoriasis imposes a significant burden on patients, and is often associated with poor quality of life,” said Dr. Lebwohl. “Effectively treating psoriasis with topical therapies, which the vast majority of patients receive, is especially challenging due to side effects, tolerability, or efficacy of existing topical treatments. Roflumilast cream could really be a game changer.”
Roflumilast which contains PDE4, an intracellular enzyme that regulates pro-inflammatory and anti-inflammatory cytokine production and cell proliferation has been implicated in a wide range of inflammatory diseases, and approved by the U.S. Food and Drug Administration for the treatment of chronic obstructive pulmonary disease (COPD) in 2011.
In the double-blinded trial, a total of 331 adults with plaque psoriasis were randomly assigned in a 1:1:1 ratio to receive topical treatment with roflumilast cream 0.3%, 0.15%, or matching treatment applied once daily for 12 weeks. A total of 109 patients were treated with roflumilast cream 0.3%, 113 with 0.15% cream, and 109 with the matching treatment. The primary efficacy outcome was investigator global assessment (IGA, a five-item scale assessing plaque thickening, scaling, and erythema, ranging from 0, clear, to 4, severe) of clear or almost clear at week six. Secondary outcomes included clear or almost clear plus a two-grade improvement (IGA success), IGA success on an intertriginous IGA, and change in psoriasis area and severity index (PASI).
Psoriasis is an immune disease that occurs in about two percent of adults in Western countries. About 90 percent of psoriasis cases are plaque psoriasis, which is characterized by “plaques,” or raised red areas of skin covered with a silver or white layer of scale. Psoriatic plaques can appear on any area of the body, but most often appear on the scalp, knees, elbows, trunk, and limbs, and the plaques are often itchy and sometimes painful. Plaques in certain anatomical areas present particular treatment challenges, including the face, elbows, knees, scalp, and other areas of the skin that may touch or rub together.
“The results from this phase 2b study data provide further evidence of the potential of roflumilast cream as a once-daily treatment for patients with plaque psoriasis who currently lack suitable treatment options,” said Howard Welgus, MD, Chief Medical Officer at Arcutis, the biopharmaceutical company, which funded and co-authored the study. “We are pleased to share these results, which suggest topical roflumilast was well tolerated and efficacious, with the broader scientific community.”
Mount Sinai is currently conducting phase 3 clinical studies with the drug.
About the Mount Sinai Health System
Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with 48,000 employees working across eight hospitals, more than 400 outpatient practices, more than 600 research and clinical labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time—discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.
Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 9,000 primary and specialty care physicians and 11 free-standing joint-venture centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida. Hospitals within the System are consistently ranked by Newsweek’s® “The World’s Best Smart Hospitals, Best in State Hospitals, World Best Hospitals and Best Specialty Hospitals” and by U.S. News & World Report's® “Best Hospitals” and “Best Children’s Hospitals.” The Mount Sinai Hospital is on the U.S. News & World Report® “Best Hospitals” Honor Roll for 2024-2025.
For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.